The Gamida Cell Ltd.-Teva Pharmaceutical Industries Limited Joint Venture Receives FDA Fast Track Designation for StemEx(R) for Leukemia and Lymphoma

Published: Jun 21, 2010

JERUSALEM--(BUSINESS WIRE)--Gamida Cell announced today that the Gamida Cell-Teva Joint Venture has received an FDA Fast Track Designation for StemEx, in development as an alternative to a bone marrow transplant for patients with blood cancers such as leukemia and lymphoma.

Back to news